EnglishFrenchGermanItalianSpanish

NeuMoDx Molecular Systems

DESIGNING AND DEVELOPING REVOLUTIONARY MOLECULAR DIAGNOSTIC SOLUTIONS

Our patented, “sample to result” platform offers market-leading ease of use, true continuous random-access and rapid turnaround time while achieving optimal operational and clinical performance for our customers and their patients.

POWERFUL. SIMPLE. DIAGNOSTICS™

The NeuMoDx™ Molecular Systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result”. The NeuMoDx™ 288 and the NeuMoDx™ 96 Molecular Systems are fully automated, continuous random-access analyzers utilizing our proprietary NeuDry™ reagent technology, which integrates magnetic particle affinity capture and real time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. This technology, combined with a platform, uniquely incorporates robotics and microfluidics resulting in higher throughput, improved performance and increased efficiency by eliminating the waste associated with technologies that require reconstitution of lyophilized reagents.

NeuMoDx has a strong IP portfolio that includes greater than 20 US patents along with corresponding foreign patents and applications.

OUR VISION

Create a scalable family of molecular testing platforms easily integrated into the molecular diagnostic process. Enable laboratory professionals to operate more efficiently and cost-effectively, thereby increasing the use of molecular diagnostic testing by medical providers to better identify and treat disease early.

Our Solutions
NEWSROOM

DISCOVER WHAT WE ARE DOING

READ ALL ABOUT IT

Our board

  • JEFF WILLIAMS
    Chairman and CEO, NeuMoDx™ Molecular JEFF WILLIAMS
    linkedin

    Jeff is the founding CEO of NeuMoDx™ Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.

    Jeff received a BS in Biology from Alma College and an MBA from the University of Michigan.

  • Bill Burkoth
    Executive Director, Pfizer Ventures Bill Burkoth
    linkedin

    Bill is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently serves on the board of directors of Biodesy, NeuMoDx™ Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and BBI Financial Gestão de Recursos (Rio, Brazil). Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

  • Jan Garfinkle
    Founder & Managing Director, Arboretum Ventures Jan Garfinkle
    linkedin

    Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering, extensive operating experience, and industry connections to select and nurture outstanding companies. Jan led Arboretum’s investment in HandyLab and served on the Board of Directors for five years until the company was acquired by Becton Dickinson. She presently serves as a director of Ebb Therapeutics, NXThera, NeuMoDx™, and Strata Oncology, and as a board observer for nVision Medical. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation.

    Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

  • Edward Michael
    Managing Partner, LionBird, and retired EVP, Diagnostic Products, Abbott Edward Michael
    linkedin

    Ed is Managing Partner at LionBird, a venture capital firm he co-founded in 2012, which focuses on investments in early stage software companies in the healthcare, commerce and business enterprise fields. Prior to founding LionBird, Ed was at Abbott Laboratories for almost 27 years, where he was Executive Vice President, Diagnostic Products and held various other executive roles in the Legal, Medical Products, and Diagnostics divisions. During his career at Abbott, he acquired and divested businesses, founded and built a new molecular diagnostics business, and developed and executed a plan to turn around the underperforming Diagnostics division. Ed served on the Board of Directors of the Cook County Health and Hospitals System from 2012-2013, and continues to work extensively with Cook County government and health care leaders on providing health care for the poor and uninsured. He is also a member of the Boards of Directors of Telesofia, VG Bio, and Ovuline.

  • Nicole Walker
    Director, Baird Capital Nicole Walker
    linkedin

    Nicole serves as a Director on Baird Capital’s Venture Capital team and focuses on healthcare investments. Prior to joining Baird Capital, Nicole was with Abbott Ventures, where she managed the strategic planning, market development, and product portfolio initiatives for multiple brands in discrete and continuous blood glucose monitoring. Before Abbott, she was with ONSET Ventures, where she specialized in seed and early-stage healthcare technology investments, and worked for Guidant Corporation where she held a variety of roles within operations, product design & development, engineering management, and marketing. Nicole received a BS in Mechanical Engineering from Stanford University, her MBA from the Kellogg School of Management and her MEM (Masters of Engineering Management) from the McCormick School of Engineering at Northwestern University.

Our Leadership

  • JEFF WILLIAMS
    Chairman and CEO, NeuMoDx™ Molecular JEFF WILLIAMS
    linkedin

    Jeff is the founding CEO of NeuMoDx™ Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.

    Jeff received a BS in Biology from Alma College and an MBA from the University of Michigan.

  • Sundu Brahmasandra
    President and COO, NeuMoDx™ Molecular Sundu Brahmasandra
    linkedin

    Sundu serves as the President of NeuMoDx™ Molecular. Most recently, he served as the President of Life Magnetics, Inc. a spin-out from the University of Michigan developing a novel, non-microscope based platform for real-time monitoring of cell growth, death, and other binding events. Prior to Life Magnetics, Sundu served as a VP of R&D/Assay Development in the Infectious Disease division at BD Diagnostics. Prior to BD, Sundu was Co-Founder and V.P. Product Development of HandyLab, Inc., where he led the development & validation of the Jaguar molecular diagnostic platform as well as proprietary nucleic acid preparation technologies and a multitude of real-time PCR assays spanning molecular diagnostics, food-borne pathogen detection, GMO testing, and other applications. HandyLab was acquired by BD in Nov 2009 for more than $275 million.

    Sundu received his BS from the Indian Institute of Technology, Chennai and a Ph.D. in Chemical Engineering from the University of Michigan in 2001.

  • Daniel Harma
    Chief Commercial Officer, NeuMoDx™ Molecular Daniel Harma
    linkedin

    Dan serves as the Chief Commercial Officer at NeuMoDx™ Molecular where he is responsible for building and leading the infrastructure to market and support the NeuMoDx™ Molecular solutions. Previously, Dan was with Abbott Diagnostics for over 25 years serving in various commercial leadership roles including Sales, Marketing, Enterprise Account Management and International General Management. He has a proven track record of hiring, developing and leading top performing commercial organizations. Dan received his Bachelors of Business Degree from the University of Wisconsin – Whitewater and MBA from Loyola University-Chicago.

  • Nahed Mohsen
    VP of Regulatory and Clinical Affairs, NeuMoDx™ Molecular Nahed Mohsen
    linkedin
Join Us

At NeuMoDx™, we work together with the common goal of designing and developing revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. We are always looking for caring, energetic individuals to join our team.

Careers